Focused On-demand Library for Transmembrane protease serine 13

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Membrane-type mosaic serine protease

Alternative UPACC:

Q9BYE2; B4DTM9; E9PIJ5; E9PRA0; F8WAJ3; J3KQC6; Q1RMF8; Q86YM4; Q96JY8; Q9BYE1


Transmembrane protease serine 13, also known as a membrane-type mosaic serine protease, plays a pivotal role in various biological processes. It is a serine protease that cleaves the proforms of PRSS8/prostasin and HGF, leading to the activation of these proteins. This activation promotes MAPK signaling and is crucial for the formation of the stratum corneum and the epidermal barrier in embryos, highlighting its significance in developmental biology.

Therapeutic significance:

Understanding the role of Transmembrane protease serine 13 could open doors to potential therapeutic strategies. Its involvement in the activation of key proteins and signaling pathways underscores its potential as a target in drug discovery efforts aimed at treating developmental disorders and diseases related to epidermal barrier dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.